# Early phase 1 Multiple Myeloma trials recruiting: 39 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 39 trials in early phase 1 for Multiple Myeloma that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Early phase 1 Multiple Myeloma trials: 39 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/early-phase-1/multiple-myeloma

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 39
- Recruiting or not yet: 39
- Read on: November 19, 2026

## Trials

The 25 newest of 39, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| July 27, 2026 | NCT07727668 | Iberdomide (CC-220) Priming to Improve T Cell Fitness Prior to Leukapheresis for Chimeric Antigen Receptor T Cell (CAR-T) Therapy for... | Sponsor not shown (see the record) | Early phase 1 | Not yet recruiting | Multiple Myeloma, Relapsed/Refractory Multiple Myeloma | 22 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07727668) |
| June 5, 2026 | NCT07628595 | Safety and Efficacy of RN9101 in the Treatment of Relapsed/Refractory Multiple Myeloma | The First Affiliated Hospital with Nanjing Medical University | Early phase 1 | Not yet recruiting | Multiple Myeloma (MM) | 19 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07628595) |
| May 11, 2026 | NCT07577206 | Single Microdose Trial- CXCR4 PET Tracer - Pharmacokinetics and Pharmacodynamics of \[68Ga\]Ga-R54, a Radiopharmaceutical Directed Toward... | National Cancer Institute, Naples | Early phase 1 | Recruiting | Advanced Solid Tumor, Multiple Myeloma | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07577206) |
| April 20, 2026 | NCT07539233 | A Clinical Study to Evaluate the Safety and Preliminary Efficacy of QI-019B in Patients With Relapsed/Refractory Multiple Myeloma. | Institute of Hematology & Blood Diseases Hospital, China | Early phase 1 | Not yet recruiting | Multiple Myeloma (MM) | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07539233) |
| March 25, 2026 | NCT07493135 | A Study of IMV102 in Patients With Relapsed/Refractory Multiple Myeloma | Suzhou Immunofoco Biotechnology Co., Ltd | Early phase 1 | Recruiting | Relapsed/Refractory Multiple Myeloma | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07493135) |
| March 9, 2026 | NCT07458659 | Clinical Study of BCMA-Targeted CAR T-Cell Injection in the Treatment of Patients With Relapsed/Refractory Multiple Myeloma | Chulalongkorn University | Early phase 1 | Not yet recruiting | Relapsed/Refractory Multiple Myeloma (MM) | 3 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07458659) |
| February 24, 2026 | NCT07429721 | A Clinical Study to Evaluate the Safety and Preliminary Efficacy of QI-019A in Patients With Relapsed/Refractory Multiple Myeloma. | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Early phase 1 | Recruiting | Multiple Myeloma (MM) | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07429721) |
| February 10, 2026 | NCT07399444 | A Clinical Study to Evaluate LVIVO-TaVec400 for the Treatment of Relapsed/Refractory Multiple Myeloma（LB2505-0001） | Institute of Hematology & Blood Diseases Hospital, China | Early phase 1 | Not yet recruiting | Multiple Myeloma (MM) | 38 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07399444) |
| January 13, 2026 | NCT07336823 | JY232(JY232) Injection in Relapsed/Refractory Multiple Myeloma | Shenzhen Genocury Biotech Co., Ltd. | Early phase 1 | Recruiting | Multiple Myeloma | 9 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07336823) |
| January 7, 2026 | NCT07322159 | IASO206 in Patients With Relapsed/Refractory Multiple Myeloma | Institute of Hematology & Blood Diseases Hospital, China | Early phase 1 | Recruiting | Relapsed/Refractory Multiple Myeloma (RRMM) | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07322159) |
| December 19, 2025 | NCT07294625 | A Clinical Study to Evaluate LVIVO-TaVec200 for the Treatment of Relapsed/Refractory Multiple Myeloma | The First Affiliated Hospital with Nanjing Medical University | Early phase 1 | Recruiting | Multiple Myeloma | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07294625) |
| November 25, 2025 | NCT07249073 | CAR19-BCMA Dual-target CAR-T in the Treatment of Relapsed / Refractory Multiple Myeloma | Institute of Hematology & Blood Diseases Hospital, China | Early phase 1 | Recruiting | Multiple Myeloma | 9 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07249073) |
| November 18, 2025 | NCT07234721 | SL4903 CAR-T Therapy for Relapsed/Refractory Multiple Myeloma | Institute of Hematology & Blood Diseases Hospital, China | Early phase 1 | Not yet recruiting | Relapsed and Refractory Multiple Myeloma (RRMM) | 9 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07234721) |
| September 22, 2025 | NCT07185490 | IASO104 for the Treatment of Patients With Relapsed/Refractory Multiple Myeloma | Institute of Hematology & Blood Diseases Hospital, China | Early phase 1 | Not yet recruiting | Relapsed/Refractory Multiple Myeloma (RRMM), Plasma Cell Leukemia (PCL) | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07185490) |
| September 22, 2025 | NCT07185477 | A Single-arm Single-center Trial of Bridging GPRC5D/CD3 Bispecific Antibody Treatment With BCMA CAR-T Cell Therapy for Relapsed/Refractory... | Institute of Hematology & Blood Diseases Hospital, China | Early phase 1 | Not yet recruiting | Relapsed/Refractory Multiple Myeloma (RRMM) | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07185477) |
| August 3, 2025 | NCT07101705 | An Open-label, Single-arm Clinical Study to Evaluate the Safety and Preliminary Efficacy of OriV508 Injection in Treating... | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Early phase 1 | Recruiting | Multiple Myeloma (MM), Non-Hodgkin Lymphoma (NHL) | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07101705) |
| July 25, 2025 | NCT07085559 | Safety and Efficacy of Metabolically Armed BCMA CAR-T Cells (Meta10-BCMA) in the Treatment of r/r Plasma Cell Neoplasms Clinical Research | Anhui Provincial Hospital | Early phase 1 | Recruiting | Multiple Myeloma (MM), Plasma Cell Leukemia (PCL), AL Amyloidosis (AL) | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07085559) |
| May 31, 2025 | NCT06999031 | A Study to Evaluate CG-105-12 in Patients With Relapsed/Refractory Multiple Myeloma | The First Affiliated Hospital of Nanchang University | Early phase 1 | Recruiting | Relapsed/Refractory, Multiple Myeloma | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06999031) |
| May 16, 2025 | NCT06976437 | A Clinical Study of Allogeneic CD19/BCMA CAR-T Cells for the Treatment of R/R B-cell Malignant Tumors | Sponsor not shown (see the record) | Early phase 1 | Recruiting | B Cell Lymphoma, Multiple Myeloma | 21 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06976437) |
| January 24, 2025 | NCT06791681 | A Study of ESO-T01 in Treating Relapsed/ Refractory Multiple Myeloma | Sponsor not shown (see the record) | Early phase 1 | Recruiting | Relapsed/ Refractory Multiple Myeloma | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06791681) |
| December 13, 2024 | NCT06732232 | A Dose Escalating Study of CD19/CD22/BCMA CAR-T Therapy in Relapsed/ Refractory Multiple Myeloma | Shanghai Cell Therapy Group Co.,Ltd | Early phase 1 | Recruiting | Relapsed, Refractory, Multiple Myeloma | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06732232) |
| December 12, 2024 | NCT06730256 | A Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/ Refractory Plasma Cell Leukemia | The First Affiliated Hospital of Soochow University | Early phase 1 | Recruiting | Relapsed/Refractory Plasma Cell Leukemia, Relapsed/Refractory Multiple Myeloma | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06730256) |
| December 5, 2024 | NCT06718270 | a Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Plasma Cell Leukemia | Shanghai Changzheng Hospital | Early phase 1 | Recruiting | Relapsed/Refractory Multiple Myeloma, Relapsed/Refractory Plasma Cell Leukemia | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06718270) |
| December 4, 2024 | NCT06717113 | A Molecular Probe Targeting BCMA for the Clinical Diagnosis of Multiple Myeloma | Peking University First Hospital | Early phase 1 | Recruiting | Multiple Myeloma and Malignant Plasma Cell Neoplasms | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06717113) |
| May 9, 2024 | NCT06407947 | Study of CT071 Injection in High Risk Newly Diagnosed Multiple Myeloma | Shanghai Changzheng Hospital | Early phase 1 | Recruiting | Multiple Myeloma | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06407947) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| Institute of Hematology & Blood Diseases Hospital, China | 7 |
| Zhejiang University | 4 |
| Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 3 |
| Shanghai Changzheng Hospital | 2 |
| Peking University First Hospital | 2 |
| The First Affiliated Hospital with Nanjing Medical University | 2 |
| Suzhou Immunofoco Biotechnology Co., Ltd | 1 |
| Augusta University | 1 |
| The First Affiliated Hospital of Nanchang University | 1 |
| Guangdong Second Provincial General Hospital | 1 |
| First Affiliated Hospital of Fujian Medical University | 1 |
| Anhui Provincial Hospital | 1 |
| The First Affiliated Hospital of Soochow University | 1 |
| Rutgers, The State University of New Jersey | 1 |
| Hrain Biotechnology Co., Ltd. | 1 |
| Chulalongkorn University | 1 |
| Shanghai Cell Therapy Group Co.,Ltd | 1 |
| [Oncotherapeutics](https://specstream.ai/data/clinical-trials/company/oncotherapeutics) | 1 |
| National Cancer Institute, Naples | 1 |
| Shenzhen Genocury Biotech Co., Ltd. | 1 |
| Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 1 |

## By country

| Country | Trials |
| --- | --- |
| China | 27 |
| United States | 6 |
| Thailand | 1 |
| Italy | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Dermatology practices in the United States](https://specstream.ai/data/businesses/dermatology-practices/united-states)
- [Tobacco companies in the United States](https://specstream.ai/data/businesses/tobacco-companies/united-states)
- [Kosher restaurants in the United States](https://specstream.ai/data/businesses/kosher-restaurants/united-states)
- [Cajun and Creole restaurants in the United States](https://specstream.ai/data/businesses/cajun-and-creole-restaurants/united-states)
- [Sandblasting companies in the United States](https://specstream.ai/data/businesses/sandblasting-companies/united-states)
- [Halal restaurants in the United States](https://specstream.ai/data/businesses/halal-restaurants/united-states)
